Search research articles
Contact Us
Filters
Showing results (161-170 of 212) with videos related to
Page
of 22
Sort By:
International Journal of Cancer
|
March 15, 1994
Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue
D W Miles, L C Happerfield, M S Naylor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1990
Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry
S M O'Reilly, R S Camplejohn, D M Barnes, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1993
Psychiatric disorder in patients with advanced breast cancer: prevalence and associated factors
K L Pinder, A J Ramírez, M E Black, et al.
Cancer Chemotherapy and Pharmacology
|
July 31, 1998
Doxorubicin pharmacokinetics: the effect of abnormal liver biochemistry tests
C J Twelves, N A Dobbs, H C Gillies, et al.
BMJ (Clinical Research Ed.)
|
February 4, 1989
Stress and relapse of breast cancer
A J Ramirez, T K Craig, J P Watson, et al.
British Journal of Cancer
|
December 1, 1994
Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer
D W Miles, L C Happerfield, P Smith, et al.
Surgery
|
March 1, 1984
A new combined approach to the conservative treatment of early breast cancer
J L Hayward, P J Winter, D Tong, et al.
BMJ (Clinical Research Ed.)
|
January 4, 1992
Appropriate chemotherapy for palliating advanced cancer
R D Rubens, K E Towlson, A J Ramirez, et al.
Endocrine-Related Cancer
|
March 19, 2004
The interaction of oestrogen receptor status and pathological features with adjuvant treatment in relation to survival in patients with operable breast cancer: a retrospective study of 2660 patients
D M Barnes, R R Millis, C E Gillett, et al.
British Journal of Cancer
|
October 1, 1996
A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer
D W Miles, K E Towlson, R Graham, et al.
Page
of 22
Search research articles
Search
Showing results (161-170 of 212) with videos related to
Sort By:
Page
of 22
International Journal of Cancer
|
March 15, 1994
Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue
D W Miles, L C Happerfield, M S Naylor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1990
Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry
S M O'Reilly, R S Camplejohn, D M Barnes, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1993
Psychiatric disorder in patients with advanced breast cancer: prevalence and associated factors
K L Pinder, A J Ramírez, M E Black, et al.
Cancer Chemotherapy and Pharmacology
|
July 31, 1998
Doxorubicin pharmacokinetics: the effect of abnormal liver biochemistry tests
C J Twelves, N A Dobbs, H C Gillies, et al.
BMJ (Clinical Research Ed.)
|
February 4, 1989
Stress and relapse of breast cancer
A J Ramirez, T K Craig, J P Watson, et al.
British Journal of Cancer
|
December 1, 1994
Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer
D W Miles, L C Happerfield, P Smith, et al.
Surgery
|
March 1, 1984
A new combined approach to the conservative treatment of early breast cancer
J L Hayward, P J Winter, D Tong, et al.
BMJ (Clinical Research Ed.)
|
January 4, 1992
Appropriate chemotherapy for palliating advanced cancer
R D Rubens, K E Towlson, A J Ramirez, et al.
Endocrine-Related Cancer
|
March 19, 2004
The interaction of oestrogen receptor status and pathological features with adjuvant treatment in relation to survival in patients with operable breast cancer: a retrospective study of 2660 patients
D M Barnes, R R Millis, C E Gillett, et al.
British Journal of Cancer
|
October 1, 1996
A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer
D W Miles, K E Towlson, R Graham, et al.
Page
of 22